Clearing the Hurdles in Chronic Rhinosinusitis With Nasal Polyps:

Program Description 

There are tremendous disease- and treatment-related burdens associated with chronic rhinosinusitis with nasal polyps (CRSwNP). Historically, chronic and high dose oral corticosteroids (OCS) were relied on to manage the chronic inflammation associated with CRSwNP, leading to significant short- and long-term toxicities for patients. Fortunately, there are now well-tolerated and effective targeted biologic therapies available that can be implemented to improve patient outcomes and quality of life. However, in the fast-paced clinical environment, health care providers (HCPs) struggle to stay up-to-date with the most recent published data and treatment recommendations.  In this interactive, case-based activity, Drs. Kathleen Buchheit and Joseph Han will discuss diagnosis and management of CRSwNP, combining evidence-based research with their expert opinions to help HCPs overcome common clinical challenges.  

Target Audience

This online and mobile continuing medical education (CME) activity is designed to address identified knowledge and practice gaps among allergy/clinical immunology, ear, nose, and throat (ENT), and pulmonology clinicians involved in the management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Discuss key pathologic processes that contribute to CRSwNP and other chronic inflammatory airway diseases
2. Assess patients with CRSwNP for symptom burden, disease phenotypes, and effects on health-related quality of life
3. Describe recent trial data and prescribing considerations for biologic therapies in the treatment of adults and adolescents with CRSwNP
4. Individualize treatment for adolescents and adults with CRSwNP to reflect disease severity, endotype, comorbidities, treatment responses, and patient preferences

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Kathleen M. Buchheit, MD: 

• Consulting Fees: AstraZeneca plc, Eli Lilly and Company, GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi
• Contracted Research: Regeneron Pharmaceuticals, Inc.

Joseph K. Han, MD:

• Consulting Fees: AstraZeneca plc, GSK plc, Sanofi

The Integritas planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com